Novartis | NOVN - Nettoeinkommen

Aktienkurs
113.43
Täglich Wechseln
-0.27 -0.24%
Monatlich
-5.33%
Jährlich
21.45%
Q2 Prognose
111.47




Nettoeinkommen Veränderung Datum
AbbVie USD 1.82B 1.63B 2025-12
Alcon AG USD 217M 20M 2025-12
Almirall EUR 19.58M 7M 2025-12
Amgen USD 1.33B 1.88B 2025-12
AstraZeneca USD 2.33B 207M 2025-12
Autolus Therapeutics Ltd USD -90.33M 11.21M 2025-12
Bayer EUR -3.76B 2.79B 2025-12
Biogen USD 466.5M 168.3M 2025-09
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Eli Lilly USD 6.64B 1.05B 2025-12
Fresenius EUR 361M 17M 2025-12
Fresenius Medical Care EUR 327M 52.2M 2025-12
Galapagos EUR 782.15M 984.26M 2025-12
Genmab DKK 31M 370M 2025-12
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
GRIFOLS EUR 98.25M 28.72M 2025-12
Hikma Pharmaceutical USD 164M 45M 2025-12
J&J USD 5.24B 119M 2026-03
Lonza CHF 426M 119M 2025-06
Merck EUR 319M 583M 2025-12
Merck USD 2.96B 2.82B 2025-12
Novartis USD 2.41B 1.52B 2025-12
Novartis USD 2.41B 1.52B 2025-12
Novo Nordisk DKK 26.89B 388M 2025-12
Orion EUR 90.4M 170.1M 2026-03
Pfizer USD -1.65B 5.19B 2025-12
Philips EUR 395M 211M 2025-12
Recordati EUR 117.31M 7.15M 2025-12
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sanofi EUR 1.61B 2.42B 2026-03
UCB EUR 1.08B 608M 2025-12